What Is New About Eosinophil Activation in Asthma and Allergic Disease

  • Akira Kanda
  • Junichi Chihara
  • Monique Capron
  • David Dombrowicz
Part of the Allergy Frontiers book series (ALLERGY, volume 2)


Eosinophils play a critical role in the pathogenesis of allergic diseases such as asthma. Prostaglandin D2 (PGD2), a lipid mediator produced by activated mast cells, and PGD2-derived prostaglandin Js (PGJs) are involved in allergic inflammation. However, PGD2 and PGJs in inflammatory conditions display both pro- and anti-inflammatory effects, hence the functional role of those lipid mediators is still controversial. PGD2 receptors, which are G protein-coupled receptors (GPCRs), the D-prostanoid receptor 1 (DP1) and the chemoattractant receptor-homologous molecule expressed on T-helper-type-2 cells (CRTH2) have been cloned. Furthermore, studies using deficient mouse and receptor-specific antibodies in vitro reveal that CRTH2 and DP1 promote and alleviate inflammation, respectively. Moreover, PGJs exerts its effects not only through DP1 and CRTH2, but also through peroxisome proliferator-activated receptor- (PPAR- ), which negatively regulates inflammation. DP1, CRTH2, and PPAR- are expressed on various inflammatory cells including eosinophils. Thus, these evidences render difficult the understanding of the functional role of PDG2 and its metabolite in allergic response involving eosinophils. Here, we examine the functional role of DP1/CRTH2 and PPAR- on eosinophilic inflammation, and discuss new therapeutic strategies for eosinophil-associated diseases focused on PGD2 and its metabolites.


Allergy Clin Immunol Airway Remodel Allergic Inflammation Eosinophilic Inflammation CD11b Expression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Duez C, Dakhama A, Tomkinson A, Marquillies P, Balhorn A, Tonnel AB, Bratton DL, Gelfand EW (2004) Migration and accumulation of eosinophils toward regional lymph nodes after airway allergen challenge. J Allergy Clin Immunol 114:820–825PubMedCrossRefGoogle Scholar
  2. 2.
    Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF (2000) Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 105:945–953PubMedCrossRefGoogle Scholar
  3. 3.
    Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O'Neill KR, Protheroe C, Pero R, Nguyen T, Cormier SA, Lenkiewicz E, Colbert D, Rinaldi L, Ackerman SJ, Irvin CG, Lee NA (2004) Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305:1773–1776PubMedCrossRefGoogle Scholar
  4. 4.
    Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, Ghiran S, Gerard NP, Yu C, Orkin SH, Gerard C (2004) A critical role for eosinophils in allergic airways remodeling. Science 305:1776–1779PubMedCrossRefGoogle Scholar
  5. 5.
    Murray JJ, Tonnel AB, Brash AR, Roberts LJ, 2nd, Gosset P, Workman R, Capron A, Oates JA (1986) Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 315:800–804PubMedGoogle Scholar
  6. 6.
    Herschman HR, Reddy ST, Xie W (1997) Function and regulation of prostaglandin synthase-2. Adv Exp Med Biol 407:61–66PubMedGoogle Scholar
  7. 7.
    Hardy CC, Robinson C, Tattersfield AE, Holgate ST (1984) The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med 311:209–213PubMedGoogle Scholar
  8. 8.
    Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255–261PubMedCrossRefGoogle Scholar
  9. 9.
    Kostenis E, Ulven T (2006) Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 12:148–158PubMedCrossRefGoogle Scholar
  10. 10.
    Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S (1994) Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 91:11192–11196PubMedCrossRefGoogle Scholar
  11. 11.
    Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP, Gervais FG (2002) Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 137:1163–1172PubMedCrossRefGoogle Scholar
  12. 12.
    Fitzpatrick FA, Wynalda MA (1983) Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem 258:11713–11718PubMedGoogle Scholar
  13. 13.
    Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K (2002) 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277:10459–10466PubMedCrossRefGoogle Scholar
  14. 14.
    Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649–688PubMedCrossRefGoogle Scholar
  15. 15.
    Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D (2003) Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 198:411–421PubMedCrossRefGoogle Scholar
  16. 16.
    Ueki S, Adachi T, Bourdeaux J, Oyamada H, Yamada Y, Hamada K, Kanda A, Kayaba H, Chihara J (2003) Expression of PPARgamma in eosinophils and its functional role in survival and chemotaxis. Immunol Lett 86:183–189PubMedCrossRefGoogle Scholar
  17. 17.
    Greene ME, Pitts J, McCarville MA, Wang XS, Newport JA, Edelstein C, Lee F, Ghosh S, Chu S (2000) PPARgamma: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat 62:45–73PubMedCrossRefGoogle Scholar
  18. 18.
    Delerive P, Fruchart JC, Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169:453–459PubMedCrossRefGoogle Scholar
  19. 19.
    Daynes RA, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2:748–759PubMedCrossRefGoogle Scholar
  20. 20.
    Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ (2000) The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164:1364–1371PubMedGoogle Scholar
  21. 21.
    Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator- activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79–82PubMedCrossRefGoogle Scholar
  22. 22.
    Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P, Delerive P, Maliszewski C, Capron M, Staels B, Moser M, Trottein F (2000) Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 486:261–266PubMedCrossRefGoogle Scholar
  23. 23.
    Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T (2000) Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol 30: 3363–3370PubMedCrossRefGoogle Scholar
  24. 24.
    Marsden KA, Rao PS, Cavanagh D, Spaziani E (1984) The effect of prostaglandin D2 (PGD2) on circulating eosinophils. Prostaglandins Leukot Med 15:387–397PubMedCrossRefGoogle Scholar
  25. 25.
    Emery DL, Djokic TD, Graf PD, Nadel JA (1989) Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol 67:959–962PubMedGoogle Scholar
  26. 26.
    Raible DG, Schulman ES, DiMuzio J, Cardillo R, Post TJ (1992) Mast cell mediators prostaglandin-D2 and histamine activate human eosinophils. J Immunol 148:3536–3542PubMedGoogle Scholar
  27. 27.
    Woodward DF, Hawley SB, Williams LS, Ralston TR, Protzman CE, Spada CS, Nieves AL (1990) Studies on the ocular pharmacology of prostaglandin D2. Invest Ophthalmol Vis Sci 31:138–146PubMedGoogle Scholar
  28. 28.
    Monneret G, Gravel S, Diamond M, Rokach J, Powell WS (2001) Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98:1942–1948PubMedCrossRefGoogle Scholar
  29. 29.
    Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H, Narumiya S (2000) Prostaglandin D2 as a mediator of allergic asthma. Science 287:2013–2017PubMedCrossRefGoogle Scholar
  30. 30.
    Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, Ohtani M, Arita H (2001) Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 298:411–419PubMedGoogle Scholar
  31. 31.
    Torisu K, Kobayashi K, Iwahashi M, Nakai Y, Onoda T, Nagase T, Sugimoto I, Okada Y, Matsumoto R, Nanbu F, Ohuchida S, Nakai H, Toda M (2004) Discovery of orally active prostaglandin D2 receptor antagonists. Bioorg Med Chem Lett 14:4891–4895PubMedCrossRefGoogle Scholar
  32. 32.
    Oguma T, Palmer LJ, Birben E, Sonna LA, Asano K, Lilly CM (2004) Role of prostanoid DP receptor variants in susceptibility to asthma. N Engl J Med 351:1752–1763PubMedCrossRefGoogle Scholar
  33. 33.
    Spik I, Brenuchon C, Angeli V, Staumont D, Fleury S, Capron M, Trottein F, Dombrowicz D (2005) Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 174:3703–3708PubMedGoogle Scholar
  34. 34.
    Angeli V, Staumont D, Charbonnier AS, Hammad H, Gosset P, Pichavant M, Lambrecht BN, Capron M, Dombrowicz D, Trottein F (2004) Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J Immunol 172:3822–3829PubMedGoogle Scholar
  35. 35.
    Arai I, Takano N, Hashimoto Y, Futaki N, Sugimoto M, Takahashi N, Inoue T, Nakaike S (2004) Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 505:229–235PubMedCrossRefGoogle Scholar
  36. 36.
    Hammad H, Kool M, Soullie T, Narumiya S, Trottein F, Hoogsteden HC, Lambrecht BN (2007) Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 204:357–367PubMedCrossRefGoogle Scholar
  37. 37.
    Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN (2003) Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 171:3936–3940PubMedGoogle Scholar
  38. 38.
    Shiraishi Y, Asano K, Nakajima T, Oguma T, Suzuki Y, Shiomi T, Sayama K, Niimi K, Wakaki M, Kagyo J, Ikeda E, Hirai H, Yamaguchi K, Ishizaka A (2005) Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther 312:954–960PubMedCrossRefGoogle Scholar
  39. 39.
    Chevalier E, Stock J, Fisher T, Dupont M, Fric M, Fargeau H, Leport M, Soler S, Fabien S, Pruniaux MP, Fink M, Bertrand CP, McNeish J, Li B (2005) Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 175:2056–2060PubMedGoogle Scholar
  40. 40.
    Satoh T, Moroi R, Aritake K, Urade Y, Kanai Y, Sumi K, Yokozeki H, Hirai H, Nagata K, Hara T, Utsuyama M, Hirokawa K, Sugamura K, Nishioka K, Nakamura M (2006) Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 177:2621–2629PubMedGoogle Scholar
  41. 41.
    Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, Nagata K (2002) Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 168:981–985PubMedGoogle Scholar
  42. 42.
    Huang JL, Gao PS, Mathias RA, Yao TC, Chen LC, Kuo ML, Hsu SC, Plunkett B, Togias A, Barnes KC, Stellato C, Beaty TH, Huang SK (2004) Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. Hum Mol Genet 13:2691–2697PubMedCrossRefGoogle Scholar
  43. 43.
    Maeda Y, Hizawa N, Takahashi D, Fukui Y, Konno S, Nishimura M (2007) Genetic impact of functional single nucleotide polymorphisms in the 3′-UTR region of the chemoattractant receptor expressed on Th2 cells (CRTH2) gene on asthma and atopy in a Japanese population. Int Arch Allergy Immunol 142:51–58PubMedCrossRefGoogle Scholar
  44. 44.
    Toyomoto M, Ohta M, Okumura K, Yano H, Matsumoto K, Inoue S, Hayashi K, Ikeda K (2004) Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Lett 562:211–215PubMedCrossRefGoogle Scholar
  45. 45.
    Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y (2002) Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 168:443–449PubMedGoogle Scholar
  46. 46.
    Honda K, Arima M, Cheng G, Taki S, Hirata H, Eda F, Fukushima F, Yamaguchi B, Hatano M, Tokuhisa T, Fukuda T (2003) Prostaglandin D2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. J Exp Med 198:533–543PubMedCrossRefGoogle Scholar
  47. 47.
    Mesquita-Santos FP, Vieira-de-Abreu A, Calheiros AS, Figueiredo IH, Castro-Faria-Neto HC, Weller PF, Bozza PT, Diaz BL, Bandeira-Melo C (2006) Cutting edge: prostaglandin D2 enhances leukotriene C4 synthesis by eosinophils during allergic inflammation: synergistic in vivo role of endogenous eotaxin. J Immunol 176:1326–1330PubMedGoogle Scholar
  48. 48.
    Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, Metters KM, O'Neill G P (2001) Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 108:982–988PubMedCrossRefGoogle Scholar
  49. 49.
    Hirai H, Abe H, Tanaka K, Takatsu K, Sugamura K, Nakamura M, Nagata K (2003) Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor. Biochem Biophys Res Commun 307:797–802PubMedCrossRefGoogle Scholar
  50. 50.
    Monneret G, Li H, Vasilescu J, Rokach J, Powell WS (2002) 15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J Immunol 168:3563–3569PubMedGoogle Scholar
  51. 51.
    Heinemann A, Schuligoi R, Sabroe I, Hartnell A, Peskar BA (2003) Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J Immunol 170:4752–4758PubMedGoogle Scholar
  52. 52.
    Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, Bacon KB (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 305:347–352PubMedCrossRefGoogle Scholar
  53. 53.
    Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M (1995) Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 270:18910–18916PubMedCrossRefGoogle Scholar
  54. 54.
    Kampen GT, Stafford S, Adachi T, Jinquan T, Quan S, Grant JA, Skov PS, Poulsen LK, Alam R (2000) Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95:1911–1917PubMedGoogle Scholar
  55. 55.
    Stubbs VE, Schratl P, Hartnell A, Williams TJ, Peskar BA, Heinemann A, Sabroe I (2002) Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem 277:26012–26020PubMedCrossRefGoogle Scholar
  56. 56.
    Xue L, Gyles SL, Barrow A, Pettipher R (2007) Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D(2). Biochem Pharmacol 73:843–853PubMedCrossRefGoogle Scholar
  57. 57.
    Kobayashi Y, Ueki S, Mahemuti G, Chiba T, Oyamada H, Saito N, Kanda A, Kayaba H, Chihara J (2005) Physiological levels of 15-deoxy-Delta12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-gamma ligation. J Immunol 175:5744–5750PubMedGoogle Scholar
  58. 58.
    Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15-Deoxydelta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803–812PubMedCrossRefGoogle Scholar
  59. 59.
    Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819PubMedCrossRefGoogle Scholar
  60. 60.
    Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698–701PubMedCrossRefGoogle Scholar
  61. 61.
    Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H (2000) 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106:189–197PubMedCrossRefGoogle Scholar
  62. 62.
    Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403:103–108PubMedCrossRefGoogle Scholar
  63. 63.
    Zhang X, Wang JM, Gong WH, Mukaida N, Young HA (2001) Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J Immunol 166:7104–7111PubMedGoogle Scholar
  64. 64.
    Bureau F, Desmet C, Melotte D, Jaspar F, Volanti C, Vanderplasschen A, Pastoret PP, Piette J, Lekeux P (2002) A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: oxidative stress-induced extracellular signal-regulated kinase activation without NF-kappa B inhibition. J Immunol 168:5318–5325PubMedGoogle Scholar
  65. 65.
    Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel P, Megret J, Leseche G, Aubier M, Pretolani M (2001) Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 164:1487–1494PubMedGoogle Scholar
  66. 66.
    Honda K, Marquillies P, Capron M, Dombrowicz D (2004) Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 113:882–888PubMedCrossRefGoogle Scholar
  67. 67.
    Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P (2003) PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 139:163–171PubMedCrossRefGoogle Scholar
  68. 68.
    Hammad H, de Heer HJ, Soullie T, Angeli V, Trottein F, Hoogsteden HC, Lambrecht BN (2004) Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 164:263–271PubMedGoogle Scholar
  69. 69.
    Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, Lee YC (2005) PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. Faseb J 19:1033–1035PubMedCrossRefGoogle Scholar
  70. 70.
    Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC (2006) Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol 118:120–127PubMedCrossRefGoogle Scholar
  71. 71.
    Matsuwaki Y, Ueki S, Adachi T, Oyamada H, Kamada Y, Yamaguchi K, Kanda A, Hamada K, Kayaba H, Chihara J (2005) The synthetic PPARgamma agonist troglitazone inhibits IL-5-induced CD69 upregulation and eosinophil-derived neurotoxin release from eosinophils. Pharmacology 74:169–173PubMedCrossRefGoogle Scholar
  72. 72.
    Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG (2002) Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gammaindependent mechanism. J Immunol 168:6232–6243PubMedGoogle Scholar
  73. 73.
    Pettipher R, Hansel TT, Armer R (2007) Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 6:313–325PubMedCrossRefGoogle Scholar
  74. 74.
    Mitsumori S, Tsuri T, Honma T, Hiramatsu Y, Okada T, Hashizume H, Kida S, Inagaki M, Arimura A, Yasui K, Asanuma F, Kishino J, Ohtani M (2003) Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-Dimethylbicyclo[3.1.1]heptane derivatives. J Med Chem 46:2446–2455PubMedCrossRefGoogle Scholar
  75. 75.
    Arakawa K, Ishihara T, Aoto M, Inamasu M, Kitamura K, Saito A (2004) An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 31:8–13PubMedCrossRefGoogle Scholar
  76. 76.
    Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106–1118PubMedCrossRefGoogle Scholar
  77. 77.
    Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2007) Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med 357(1):28–38PubMedCrossRefGoogle Scholar
  78. 78.
    Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRefGoogle Scholar
  79. 79.
    Belvisi MG, Hele DJ, Birrell MA (2006) Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 533:101–109PubMedCrossRefGoogle Scholar
  80. 80.
    Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Mutoh S (2007) Mechanism by which a novel non-thiazolidinedione peroxisome proliferatoractivated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. Diabetes Obes Metab 9:369–378PubMedCrossRefGoogle Scholar
  81. 81.
    Powell WS (2003) A novel PGD(2) receptor expressed in eosinophils. Prostaglandins Leukot Essent Fatty Acids 69:179–185PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Akira Kanda
    • 1
  • Junichi Chihara
    • 2
  • Monique Capron
    • 1
  • David Dombrowicz
    • 1
  1. 1.Inserm U547, Université Lille 2, Institut Pasteur de Lille 1Lille CedexFrance
  2. 2.Department of Clinical and Laboratory MedicineAkita University School of MedicineAkitaJapan

Personalised recommendations